Brand Reference: Cytomel
| Metric | Verified Benchmark | Source |
|---|---|---|
| Liothyronine Sodium (Bioactive L-Triiodothyronine T3) RxNorm Concept ID | 10594 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $78.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $11.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $15.00 / mo | 28 Zero-PHI Verified Patient Logs |
Supplies active 3,3-prime,5-triiodo-L-thyronine directly with 10-fold higher nuclear TR-beta/TR-alpha binding affinity than T4, bypassing defective peripheral DIO2 Thr92Ala polymorphism conversion in patients remaining symptomatic despite normal TSH on T4 monotherapy.
Across 28 community cost disclosures for Liothyronine Sodium (Bioactive L-Triiodothyronine T3) (Cytomel), cash buyers routing around $78.00 retail markups capture a 85% discount ($11.90/mo benchmark vs $0.3400 NADAC acquisition).
Following administration (5 mcg PO QAM (or 2.5 mcg BID)), Liothyronine Sodium (Bioactive L-Triiodothyronine T3) achieves 95% oral bioavailability and 2–4 hours serum t3 peak (split bid dosing avoids afternoon crash) onset, governed by a ~24–30 hours biological / 19–22 hours plasma terminal half-life through deiodination to diiodothyronine (t2) and hepatic sulfation.
Before initiating Liothyronine Sodium (Bioactive L-Triiodothyronine T3) at 5 mcg PO QAM (or 2.5 mcg BID), clinical safety checklists rule out untreated adrenal insufficiency; unstable angina or atrial tachyarrhythmia. Logged tolerability patterns center on midday resting pulse bump (+8 bpm) (16% of reports), afternoon dip if dosed once daily (14% of reports).
Across 28 verified cash-pay logs, Liothyronine Sodium (Bioactive L-Triiodothyronine T3) achieves a 90.60% Worth-It rating with out-of-pocket spend averaging $15.00/mo versus $78.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mcg PO QAM (or 2.5 mcg BID) for Liothyronine Sodium (Bioactive L-Triiodothyronine T3); monthly out-of-pocket dropped to $10.47 compared with $78.00 retail.
Completed 10 weeks on Liothyronine Sodium (Bioactive L-Triiodothyronine T3) (5 mcg PO BID alongside T4). Zero notable side effects on steady dosing.
Consistent biomarker response on 12.5–25 mcg PO daily Liothyronine Sodium (Bioactive L-Triiodothyronine T3) sourced via Cash Clinic ($13.80/mo cash pay without insurance prior authorization).